nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2005-9-4-19-24nefr-710Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESБЛОКАДА ПОЧЕЧНЫХ МИНЕРАЛКОРТИКОИДНЫХ РЕЦЕПТОРОВ: НОВЫЙ ПОДХОД К НЕФРОПРОТЕКТИВНОЙ ТЕРАПИИ ГИПЕРТЕНЗИВНЫХ БОЛЬНЫХ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕКBLOCKADE OF RENAL MINERALCORTICOID RECEPTORS: A NEW APPROACH TO NEPHROPROTECTIVE THERAPY OF HYPERTENSIVE PATIENTS WITH CHRONIC KIDNEY DISEASEКузьминО. Б.KuzminO. B.

Кафедра фармакологии

ПугаеваМ. О.PugaevaM. O.

Кафедра фармакологии

БучневаН. В.BuchnevaN. V.

Кафедра фармакологии

Оренбургской государственной медицинской академииRussian Federation200510042005941924Copyright © Кузьмин О.Б., Пугаева М.О., Бучнева Н.В., 20052005Кузьмин О.Б., Пугаева М.О., Бучнева Н.В.Kuzmin O.B., Pugaeva M.O., Buchneva N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/710

Блокада почечных минералкортикоидных рецепторов: новый подход к нефропротективной терапии гипертензивных больных с хронической болезнью почек.

Blockade of renal mineralcorticoid receptors: a new approach to nephroprotective therapy of hypertensive patients with chronic kidney disease.

артериальная гипертонияхроническая болезнь почекальдостеронблокада минералкортикоидных рецепторовarterial hypertensionchronic kidney diseasealdosteronealdosterone receptor blockadeReferencesChobanian A, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42 (6): 12061252Chobanian A, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42 (6): 12061252Guidelines Committee. 2003 European Society of hypertension / European Society of cardiology guidelines for management of arterial hypertension. J Hypertens 2003; 21 (6): 10111053Guidelines Committee. 2003 European Society of hypertension / European Society of cardiology guidelines for management of arterial hypertension. J Hypertens 2003; 21 (6): 10111053Комитет экспертов ВНОК. Профилактика, диагнос тика и лечение артериальной гипертонии. Российские ре комендации (второй пересмотр). Кардиоваскулярная терапия и профилактика 2004; 6 (Приложение): 319Комитет экспертов ВНОК. Профилактика, диагнос тика и лечение артериальной гипертонии. Российские ре комендации (второй пересмотр). Кардиоваскулярная терапия и профилактика 2004; 6 (Приложение): 319Hall WD. A rationale approach to the treatment of hypertension in special population. Am Fam Physician 1999; (2): 156162Hall WD. A rationale approach to the treatment of hypertension in special population. Am Fam Physician 1999; (2): 156162Sato A, Saruta T. Aldosterone escape during angiotensin converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29 (1): 1321Sato A, Saruta T. Aldosterone escape during angiotensin converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29 (1): 1321Oberleithner H, Ludwig T, Riethmuller C et al. Human endothelium: target for aldosterone. Hypertension 2004; 43 (5): 952957Oberleithner H, Ludwig T, Riethmuller C et al. Human endothelium: target for aldosterone. Hypertension 2004; 43 (5): 952957Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in glomerular microcirculation. J Am Soc Nephrol 2003; 14 (9): 22552253Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in glomerular microcirculation. J Am Soc Nephrol 2003; 14 (9): 22552253ToddTurla KM, Schnermann J, FejesToth G et al. Distribution of mineralcorticoid and glucocorticoid receptor mRNA along the nephron. Am J Physiol 1993; 264 (5, Pt2): F781 F789ToddTurla KM, Schnermann J, FejesToth G et al. Distribution of mineralcorticoid and glucocorticoid receptor mRNA along the nephron. Am J Physiol 1993; 264 (5, Pt2): F781 F789Komel L. Colocalisation of 11βhydroxysteroid dehydrogenase and mineralcorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994; 7 (2): 100103Komel L. Colocalisation of 11βhydroxysteroid dehydrogenase and mineralcorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994; 7 (2): 100103Lai LJ, Gu Y, Chen J et al. Production of aldosterone by rat mesangial cell and accumulation of extracellular matrix induced by aldosterone. Zhounghua Yi Xu 2003; 83 (21): 19001905Lai LJ, Gu Y, Chen J et al. Production of aldosterone by rat mesangial cell and accumulation of extracellular matrix induced by aldosterone. Zhounghua Yi Xu 2003; 83 (21): 19001905Jucknevicius I, Segal Y, Kren S et al. Effect of aldosterone on renal transforming growth factorbeta. Am J Physiol 2004; 286 (6): F1059F1062Jucknevicius I, Segal Y, Kren S et al. Effect of aldosterone on renal transforming growth factorbeta. Am J Physiol 2004; 286 (6): F1059F1062Krug AW, Grossmann C, Schuster C et al. Aldosterone stimulates epidermal growth factor receptor expression. J Biol Chem 2003; 278 (44): 43604366Krug AW, Grossmann C, Schuster C et al. Aldosterone stimulates epidermal growth factor receptor expression. J Biol Chem 2003; 278 (44): 43604366Brown NJ, Nakamura S, Ma L et al. Aldosterone stimulates plasminogen activator inhibitor1 and glomerulosclerosis in vivo. Kidney Int 2000; 58 (5): 12191227Brown NJ, Nakamura S, Ma L et al. Aldosterone stimulates plasminogen activator inhibitor1 and glomerulosclerosis in vivo. Kidney Int 2000; 58 (5): 12191227Eddy AA. Plasminogen activator inhibitor1 and the kidney. Am J Physiol 2002; 283 (20): F209F223Eddy AA. Plasminogen activator inhibitor1 and the kidney. Am J Physiol 2002; 283 (20): F209F223Nishiyama A, Abe Y. Aldosterone and renal injury. Folia Pharmacol Jap 2004; 124 (2): 101109Nishiyama A, Abe Y. Aldosterone and renal injury. Folia Pharmacol Jap 2004; 124 (2): 101109Blasi ER, Rocha R, Rudolph AE et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63 (5): 17911800Blasi ER, Rocha R, Rudolph AE et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63 (5): 17911800DeLano FA, SchmidSchonbein GW. Enhancement of glucocorticoid and mineralcorticoid receptor density in the microcirculation of the spontaneously hypertensive rat. Microcirculation 2004; 11 (1): 6869DeLano FA, SchmidSchonbein GW. Enhancement of glucocorticoid and mineralcorticoid receptor density in the microcirculation of the spontaneously hypertensive rat. Microcirculation 2004; 11 (1): 6869Takeda Y. Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol 2004; 217 (12): 7579Takeda Y. Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol 2004; 217 (12): 7579Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes and angiotensin II type 1 receptor. Hypertension 2005; 46 (3): 584591Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes and angiotensin II type 1 receptor. Hypertension 2005; 46 (3): 584591Zhou X, Ono H, Frohlich ED. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in LNAME/SHR model. Am J Nephrol 2004; 24 (2): 242249Zhou X, Ono H, Frohlich ED. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in LNAME/SHR model. Am J Nephrol 2004; 24 (2): 242249Rocha R, Chander PN, Khanna K et al. Mineralcorticoid blockade reduces vascular injury in strokeprone hypertensive rats. Hypertension 1998; 31 (1): 451452Rocha R, Chander PN, Khanna K et al. Mineralcorticoid blockade reduces vascular injury in strokeprone hypertensive rats. Hypertension 1998; 31 (1): 451452Hao L, Kanno Y, Fukushima R et al. Effects of eplerenone on heart and kidney in twokidney, one clip rats. Am J Nephrol 2004; 24 (1): 5460Hao L, Kanno Y, Fukushima R et al. Effects of eplerenone on heart and kidney in twokidney, one clip rats. Am J Nephrol 2004; 24 (1): 5460de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesityinduced hypertension and glomerular hyperfiltration. Hypertension 2004; 43 (1): 4147de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesityinduced hypertension and glomerular hyperfiltration. Hypertension 2004; 43 (1): 4147Bayorh MA, Ganafa AA, Emmett N et al. Alterations in aldosterone and angiotensin II levels in saltinduced hypertension. Clin Exp Hypertens 2005; 27 (4): 355367Bayorh MA, Ganafa AA, Emmett N et al. Alterations in aldosterone and angiotensin II levels in saltinduced hypertension. Clin Exp Hypertens 2005; 27 (4): 355367Кузьмин ОБ, Пугаева МО. Нейрогуморальный дис баланс как причина дисфункции почки при первичной ар териальной гипертонии. Нефрология 2004; 8 (1): 2226Кузьмин ОБ, Пугаева МО. Нейрогуморальный дис баланс как причина дисфункции почки при первичной ар териальной гипертонии. Нефрология 2004; 8 (1): 2226Prisant LM, Krum H, Roniker B et al. Can renin status predict the antihypertensive efficacy of eplerenone addon therapy? J Clin Pharmacol 2003; 43 (11): 12031210Prisant LM, Krum H, Roniker B et al. Can renin status predict the antihypertensive efficacy of eplerenone addon therapy? J Clin Pharmacol 2003; 43 (11): 12031210Saruta T, Kageyama S, Ogihara T et al. Efficacy end safety of selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, doubleblind, placebocontrolled, dose ranging study. J Clin Hypertens (Greenwich) 2004; 6 (4): 175183Saruta T, Kageyama S, Ogihara T et al. Efficacy end safety of selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, doubleblind, placebocontrolled, dose ranging study. J Clin Hypertens (Greenwich) 2004; 6 (4): 175183Schjoedt KJ, Andersen S, Rossing P et al. Aldosterone escape during blockade of reninangiotensinaldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47 (11): 19361939Schjoedt KJ, Andersen S, Rossing P et al. Aldosterone escape during blockade of reninangiotensinaldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47 (11): 19361939Rachmani R, Slavachevsky I, Amit M et al. The effect of aldosterone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephrophaty is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21 (5): 471475Rachmani R, Slavachevsky I, Amit M et al. The effect of aldosterone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephrophaty is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21 (5): 471475Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46 (1): 4551Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46 (1): 4551Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralcorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18 (1): 4449Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralcorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18 (1): 4449White WB, Duprez D, St Hillaire R et al. Effects of selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41 (5): 10211026White WB, Duprez D, St Hillaire R et al. Effects of selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41 (5): 10211026Williams GH, Burges E, Kolloch RE et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93 (8): 990996Williams GH, Burges E, Kolloch RE et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93 (8): 990996Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E left ventricular hypertrophy study. Circulation 2003; 108 (15): 18311838Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E left ventricular hypertrophy study. Circulation 2003; 108 (15): 18311838Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mildto moderate hypertension. Am J Hypertens 2002; 15 (8): 709716Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mildto moderate hypertension. Am J Hypertens 2002; 15 (8): 709716Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to reninangiotensin blockade in hypertensive patients. Hypertension 2002; 40 (2): 117123Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to reninangiotensin blockade in hypertensive patients. Hypertension 2002; 40 (2): 117123

The authors declare that there are no conflicts of interest present.